Aclaris shareholders elect directors, approve executive pay at 2026 annual meeting

Aclaris Therapeutics, Inc.

80.55% of shares voted; 112,499,671 of 139,663,680 outstanding shares represented.
Elected Anand Mehra and Maxine Gowen as directors with 83.1M and 84.2M votes for, respectively.
Advisory vote on named executive officer compensation approved: 83.4M for, 9.7M against.
Ratification of PricewaterhouseCoopers as auditor passed with 112.3M votes for.
Broker non-votes of 19.4M on proposals 1 and 2; no broker non-votes on auditor ratification.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Aclaris Therapeutics, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The stockholders ratified the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Aclaris Therapeutics, Inc. shareholders approved Advisory approval of the compensation of the Company’s named executive officers at the 2026-06-04 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Aclaris Therapeutics, Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting at the 2026-06-04 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The stockholders elected two nominees to serve as directors on the Board of Directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified.

View on SEC.gov

406 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-070494

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.